Denali Capital Acquisition Corp.(DECAU) - 2025 Q4 - Annual Report

Product Development and Clinical Trials - SP-102 is being developed as an injectable viscous gel formulation of a corticosteroid, targeting the unmet needs in acute and chronic pain management, specifically for sciatica, with over 12 million off-label epidural steroid injections administered annually in the U.S.[23] - The pivotal Phase 3 study for SP-102 achieved primary and secondary endpoints, showing a statistically significant reduction in pain intensity with a least square mean treatment difference of -0.52 units (P=0.002) compared to placebo[24] - The key secondary endpoint of mean change in Oswestry Disability Index (ODI) showed a LS mean treatment difference of -3.38 units (P=0.015), with a reduction of -8.88 points from baseline, exceeding the minimal clinically important difference[25] - Following a Type C meeting with the FDA in November 2023, the company was advised to conduct a confirmatory trial due to insufficient data from the initial study, leading to the design of the Phase 3 CLEAR-2 trial[26] - The CLEAR-2 trial is expected to enroll approximately 700 patients and will include a larger safety database to validate the safety and efficacy of SP-102, with a primary endpoint of average daily NPRS pain over four weeks[26] - The company anticipates completing the CLEAR-2 trial by 2027 and aims to submit a 505(b)(2) NDA to the FDA for SP-102 approval, targeting a commercial launch in 2028 if approved[27] - SP-102 has received fast track designation from the FDA, which may facilitate its development and regulatory review process, although it does not guarantee marketing approval[29] - SP-102 is a Phase 3 sterile dexamethasone sodium phosphate viscous gel formulation containing 10 mg of dexamethasone at a concentration of 5 mg/mL, designed for epidural injection[49] - The pivotal Phase 3 CLEAR trial enrolled 401 subjects across over 40 clinical sites in the U.S., evaluating the analgesic effect of SP-102 compared to placebo[52][55] - The primary endpoint showed a statistically significant reduction in average daily NPRS pain score of -1.81 for SP-102 versus -1.29 for placebo, with a treatment difference of -0.52 (P=0.002)[60][62] - SP-102 demonstrated a significant improvement in the key secondary endpoint of mean change in ODI from baseline, with a treatment difference of -3.38 (P=0.015)[64] - The time to repeat injection for SP-102 was 84 days compared to 58 days for placebo (P=0.001), indicating prolonged pain relief[64] - No serious adverse events (SAEs) related to SP-102 were reported, with a slightly higher proportion of treatment-emergent adverse events (TEAEs) in the SP-102 group (29.7%) compared to placebo (21.1%)[64] - SP-102 is expected to improve tolerability and pain relief by avoiding neurotoxic preservatives and particulates found in currently used steroids[50][51] - If approved, SP-102 could be the first FDA-approved epidural steroid injection product for sciatica, potentially reducing the need for spinal surgery and opioid use[51] - The Phase 3 study results were published in PAIN® Journal in June 2024, highlighting the clinical benefits of SP-102[53][59] - SP-102 demonstrated a mean change in NPRS Average Pain Score in the affected leg of -1.81 compared to -1.29 for placebo, with a statistically significant difference of -0.55 (P=0.003) [66] - The ODI total score showed a mean change of -8.88 for SP-102 versus -5.48 for placebo, resulting in a significant difference of -3.38 (P=0.015) [66] - In the ITT population, 35.1% of patients on SP-102 reported being "very much improved" or "much improved" compared to 19.6% for placebo (P<0.001) [68] - The time to repeat injection for SP-102 was significantly longer, with a mean of 67.0 days compared to 57.8 days for placebo (P=0.001) [70] - A total of 66.3% of patients receiving SP-102 required a repeat injection, while 76.4% of those on placebo did, indicating a significant difference (P=0.026) [70] - For a 30% reduction in pain, 43.6% of SP-102 patients responded positively compared to 28.6% for placebo (P=0.002) [71] - The Phase 1 trial showed a Tmax of 4 hours for SP-102 compared to 15 minutes for intravenous dexamethasone, indicating a prolonged effect [82] - SP-102 maintained analgesic effects throughout a one-month observation period, with continuous reduction in pain reported by all subjects [83] - The pharmacokinetics of SP-102 showed similar systemic exposure to dexamethasone as intravenous administration, with a mean AUCinf of 0.916 µg*h/mL for SP-102 [83] - Toxicology studies indicated no new unexpected findings, supporting the selection of a 10mg dexamethasone dose for further clinical studies [86] Market Potential and Financial Projections - The U.S. ESI market is projected to grow at an average rate of 3.6% annually through 2027, with SP-102 expected to capture a maximum market share of approximately 33%[40] - By the fifth year post-launch, SP-102 sales in sciatica are projected to reach between $1.5 billion and $2.0 billion annually, assuming regulatory approval in 2027 and commercial launch in 2028[41] - The estimated lifetime incidence of sciatica in the U.S. ranges from 13% to 40%, with over 4.8 million patients expected to suffer from sciatica in 2024[39] - Scilex has successfully launched three commercial non-opioid pain management products in the past five years, leveraging its integrated commercial infrastructure[31] - The company plans to file for a separate J code for SP-102 to facilitate reimbursement and faster revenue uptake following FDA approval[30] - Current opioid prescriptions for low back pain have increased significantly, highlighting the need for effective non-opioid alternatives like SP-102[30] - The company aims to expand its product portfolio by developing or acquiring non-opioid assets to address unmet pain management needs[30] Corporate Structure and Agreements - The Transition Services Agreement with Scilex allows the company to utilize Scilex's resources for finance, HR, and commercialization support for three years post-business combination[31] - The company has invested significantly in building its intellectual property portfolio and infrastructure since its founding in 2013, conducting various pharmacokinetic and toxicology studies[22] - The company aims to leverage the regulatory approval pathway under Section 505(b)(2) of the FDCA for its product candidate, SP-102[28] - Scilex agreed to pay up to $280.0 million in contingent cash consideration to former holders of Legacy Semnur's capital stock based on milestone achievements[114] - Payments include $40.0 million upon FDA approval of a New Drug Application (NDA) and additional payments based on cumulative net sales milestones of $100.0 million, $250.0 million, $500.0 million, and $750.0 million[114] - Legacy Semnur has not triggered any of the aforementioned payments to date[114] - The Shah Assignment Agreement stipulates royalties of 1.5% on net sales up to $250.0 million and 2.5% on net sales above that threshold, with no payments triggered to date[117] - The company's patent portfolio includes approximately seven issued and unexpired U.S. patents and two pending U.S. patent applications as of December 31, 2025[122] - SP-102 is protected by U.S. patents that expire in 2036, covering formulations and methods of treatment[123] - The company is in discussions with Sanofi to secure future supply requirements for sodium hyaluronate, a key excipient for SP-102, after the previous supply agreement with Genzyme ended on May 31, 2024[127] - The company initiated the Phase 3 CLEAR 2 trial for SP-102 in September 2025[137] Regulatory Environment - The FDA requires at least two adequate and well-controlled Phase 3 clinical trials for NDA approval, although a single trial may suffice under certain conditions[136] - The FDA has a goal of 10 months from the date of filing a standard NDA for a new molecular entity to review and act on the submission, typically taking 12 months from submission[144] - The FDA may require a Risk Evaluation and Mitigation Strategy (REMS) if deemed necessary, which could restrict commercial promotion and distribution of the product[146] - The FDA conducts a preliminary review of all NDAs within the first 60 days after submission to determine completeness for substantive review[144] - If a Complete Response Letter is issued, the sponsor must address deficiencies and resubmit the NDA, which may require additional clinical data[148] - The FDA may impose post-approval requirements, including Phase 4 clinical trials, to monitor the product's safety and effectiveness after commercialization[158] - Drug product manufacturers must register with the FDA and are subject to periodic inspections for compliance with cGMP regulations[159] - The FDA's fast track designation expedites the review process for products intended to treat serious conditions and address unmet medical needs[150] - Products may also be eligible for priority review, which aims to complete the review within six months compared to ten months for standard NDAs[152] - The breakthrough therapy designation allows for more intensive FDA interaction and guidance for products showing substantial improvement over existing therapies[154] - The FDA may withdraw approval if compliance with regulatory standards is not maintained or if new risks are discovered post-approval[158] - The Hatch-Waxman Amendments allow for three types of NDAs, including 505(b)(1) and 505(b)(2) NDAs, which enable applicants to rely on existing FDA findings for approval[160] - Section 505(j) establishes an abbreviated approval process for generic drugs through ANDAs, requiring bioequivalence testing to confirm therapeutic equivalence[161] - NDA sponsors must list all relevant patents with the FDA, and upon ANDA submission, must certify the status of these patents, which can affect approval timelines[162] - The Hatch-Waxman Amendments provide five years of exclusivity for new drug products containing new chemical entities and three years for certain changes requiring new clinical trials[164] Market Dynamics and Compliance - Third-party payors significantly influence product sales through coverage and reimbursement decisions, which can vary widely among different payors[165] - The pharmaceutical industry faces pricing pressures due to managed healthcare trends and government interest in cost containment, which may adversely affect net revenue[166] - In the EEA, governments control pharmaceutical pricing and reimbursement, creating barriers for new product entry and influencing market dynamics[167] - The Affordable Care Act (ACA) has introduced significant changes to healthcare financing, impacting the pharmaceutical industry through various provisions[168] - Legislative changes since the ACA, such as the Budget Control Act of 2011, have reduced Medicare payments, potentially affecting the ability to develop and market new products[171] - The Inflation Reduction Act of 2022 allows CMS to negotiate prices for certain high-cost drug products starting with 10 products in 2026, increasing to 20 products by 2029[172] - Medicare beneficiaries' annual out-of-pocket drug expenses are capped at $2,000 under the new legislation[172] - Pharmaceutical manufacturers face civil monetary penalties for non-compliance with negotiated pricing and for price increases exceeding inflation rates[172] - The FDA authorized Florida's drug importation program in January 2024, allowing importation of certain prescription drugs from Canada[172] - The implementation of healthcare reforms may lead to reduced reimbursement rates from Medicare, impacting future revenue[174] - Compliance with various federal and state regulations, including the Anti-Kickback Statute and the False Claims Act, is critical to avoid substantial penalties[175][178] - The Physician Payments Sunshine Act requires manufacturers to report payments to physicians and teaching hospitals, with extended obligations for non-physician providers effective January 1, 2022[184] - Several states have enacted laws requiring pharmaceutical companies to establish marketing compliance programs and report on sales and marketing activities[186] - Compliance with evolving data privacy laws, such as the CCPA and CPRA, imposes significant operational costs and risks for the company[181][183] - The company must adhere to government price reporting requirements under Medicaid and Medicare, necessitating substantial rebates and discounts[187] - The company may face significant penalties, including fines and operational restrictions, if found in violation of federal and state laws[188] Company Structure and Workforce - As of December 31, 2025, the company has 10 full-time employees, including three with M.D.s or Ph.D.s, and relies on 15 employees and contractors from Scilex for operations[210] - Scilex has 28 full-time employees, with four in R&D, seven in sales and marketing, and 17 in general management and administration[210] - The Transition Services Agreement with Scilex allows the company to utilize Scilex's employees for various business functions on a cost plus 10% basis, capped at $2.0 million per annum until the Scilex-Oramed Note of $101.9 million is fully paid[211] - The Transition Services Agreement is set for three years, providing sufficient time for the company to develop its commercial infrastructure[211] - The company was incorporated as "Denali Capital Acquisition Corp." on January 5, 2022, and changed its name to "Semnur Pharmaceuticals, Inc." on September 22, 2025, following a business combination[212] - The company qualifies as an "emerging growth company," allowing it to benefit from various reporting exemptions[212] - The company is also classified as a "smaller reporting company," which permits reduced disclosure obligations, including only two years of audited financial statements[213] - The company files reports with the SEC, which can be accessed on the SEC's website[214]